Amplify Weight Loss Drug & Treatment ETF
Amplify Weight Loss Drug & Treatment ETF reported 21 holdings worth US$4.36M as of Jun 30, 2026 (Form N-PORT)
As of Jun 30, 2026 · Filed Aug 28, 2026
Amplify Weight Loss Drug & Treatment ETF reported 21 holdings worth US$4.36M as of Jun 30, 2026. Largest: Novo Nordisk A/s Class B, Eli Lilly And Company and Scholar Rock Holding Corporation. Filed Aug 28, 2026 (Form N-PORT).
- Holdings
- 21
- Value as reported
- US$4.36M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Novo Nordisk A/s Class B | 9,001 | US$426K | 9.8% |
| Eli Lilly And Company | 337 | US$404K | 9.3% |
| Scholar Rock Holding Corporation | 4,531 | US$249K | 5.7% |
| Hims & Hers Health, Inc. | 7,013 | US$243K | 5.6% |
| Viking Therapeutics, Inc. | 6,142 | US$240K | 5.5% |
| Abbvie Inc. | 901 | US$227K | 5.2% |
| Arrowhead Pharmaceuticals, Inc. | 2,722 | US$222K | 5.1% |
| Innovent Biologics, Inc. | 21,500 | US$218K | 5.0% |
| Amgen Inc. | 552 | US$200K | 4.6% |
| Chugai Pharmaceutical Co., Ltd. | 4,300 | US$199K | 4.6% |
| Merck & Company, Inc. | 1,550 | US$199K | 4.6% |
| Astrazeneca Plc | 1,049 | US$199K | 4.6% |
| Roche Holding Ltd | 478 | US$197K | 4.5% |
| Regeneron Pharmaceuticals, Inc. | 314 | US$196K | 4.5% |
| Cspc Pharmaceutical Group Limited | 220K | US$196K | 4.5% |
| Pfizer, Inc. | 7,957 | US$192K | 4.4% |
| Zealand Pharma A/s | 3,434 | US$152K | 3.5% |
| Kailera Therapeutics, Inc. | 4,864 | US$107K | 2.5% |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A | 12,858 | US$98,850 | 2.3% |
| Hanmi Pharmaceutical Co., Ltd. | 341 | US$87,490 | 2.0% |
| Shionogi & Co., Ltd. | 0 | US$0 | 0.00% |